In 50 patients with cirrhosis and covert hepatic encephalopathy, rifaximin v no treatment for 12 weeks gave a non-significant trend to greater Stroop test improvement (-4.45 v -0.98 s, p=0.056); cirrhosis-related adverse events, a secondary outcome, were fewer with rifaximin.
RCTn = 50 patients
Inada et al. Rifaximin Improves Cognitive Performance and Reduces Cirrhosis-Related Adverse Events in Covert Hepatic Encephalopathy: A Randomized Controlled Trial